Please use this identifier to cite or link to this item: http://localhost:8080/xmlui/handle/123456789/9232
Full metadata record
DC FieldValueLanguage
dc.contributor.author-Shuo Zhao, Tian-
dc.contributor.authorLong Zeng, Hao--
dc.contributor.authorZhang, Xin-
dc.contributor.authorChen, Xi-
dc.contributor.authorLi Jiang, Wan--
dc.contributor.authorDu, Juan-
dc.date.accessioned2024-12-18T04:27:56Z-
dc.date.available2024-12-18T04:27:56Z-
dc.date.issued2022-06-01-
dc.identifier.issn1684-1182-
dc.identifier.urihttp://localhost:8080/xmlui/handle/123456789/9232-
dc.description.abstractAbstract Background: To explore the development of central nervous system (CNS) symptoms and clinical application in predicting the clinical outcomes of SARS-COV-2 patients. Methods: A retrospective cohort study was performed on the hospitalized patients with SARSCOV-2 recruited from four hospitals in Hubei Province, China from 18 January to 10 March 2020. The patients with CNS symptoms were determined. Data regarding clinical symptoms and laboratory tests were collected from medical records.Results: Of 1268 patients studied, 162 (12.8%) had CNS symptoms, manifested as unconsciousness (71, 5.6%), coma (69, 5.4%), dysphoria (50, 3.9%), somnolence (34, 2.7%) and convulsion (3, 0.2%), which were observed at median of 14 (interquartile range 9e18) days after symptom onset and significantly associated with older age (OR Z 5.71, 95% confidence interval [CI] 2.78 e11.73), male (OR Z 1.73, 95% CI 1.22e2.47) and preexisting hypertension (OR Z 1.78, 95% CI 1.23e2.57). The presence of CNS symptoms could be predicted by abnormal laboratory tests across various clinical stages, including by lymphocyte counts of <0.93 109 /L, LDH435 U/L and IL-628.83 pg/L at 0e10 days post disease; by lymphocyte count<0.86 109 /L, IL2R 949 U/L, LDH382 U/L and WBC8.06 109 /L at 11e20 days post disease. More patients with CNS symptoms developed fatal outcome compared with patients without CNS symptoms (HR Z 33.96, 95% CI 20.87e55.16). Conclusion: Neurological symptoms of COVID-19 were related to increased odds of developing poor prognosis and even fatal infection.en_US
dc.language.isoenen_US
dc.publisherElsevier Taiwan LLCen_US
dc.subjectCentral nervous systemen_US
dc.subject; SARS-CoV-2;en_US
dc.subjectFatal outcome;en_US
dc.subjectPredictionen_US
dc.titleNeurological manifestations in COVID-19 patients and their application in predicting fatal disease: A retrospective cohort studyen_US
dc.typeArticleen_US
Appears in Collections:VOL 55 NO 3 2022

Files in This Item:
File Description SizeFormat 
445-453.pdf812.07 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.